Zopiclone as a Potent Positive Control for Assessing the Residual Effects of Hypnotic Drugs on Next Day Driving Performance: A Systematic Review
- PMID: 40448946
- DOI: 10.1002/hup.70007
Zopiclone as a Potent Positive Control for Assessing the Residual Effects of Hypnotic Drugs on Next Day Driving Performance: A Systematic Review
Abstract
Aim: This systematic review aimed to evaluate the efficacy of zopiclone as a potent positive control for the assessment of residual effects of hypnotic drugs on the next day driving performance in clinical trials.
Methodology: Online databases and websites were used to conduct a literature search to identify relevant clinical trials encompassing the use of zopiclone as a positive control and the trials examining the residual effects of zopiclone on the next day driving performance. A total of 22 articles were identified and as per the inclusion criteria, 16 were selected for final data retrieval.
Results: The average difference in Standard Deviation of Lateral Position (SDLP) between zopiclone and a placebo ranged from 1.6 to 4.74 cm. On average, this difference was about 2.51 cm, indicating significant impairment in driving ability the day after taking zopiclone. Therefore, current studies demonstrate zopiclone administration impairs driving performance, as indicated by increased standard deviation of lateral position (SDLP) values. Additionally, the reported adverse events included somnolence, dyspepsia, fatigue, headache, dizziness, gastrointestinal disorders, and upper respiratory tract problems.
Conclusion: Zopiclone can serve as a reliable positive control in future clinical trials assessing the residual effects of hypnotic drugs on next-day driving performance.
Keywords: cognitive effects; driving safety; psychomotor functions; safety; sleep medication.
© 2025 John Wiley & Sons Ltd.
References
-
- Atkin, T., S. Comai, and G. Gobbi. 2018. “Drugs for Insomnia Beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery.” Pharmacological Reviews 70, no. 2 (April): 197–245. https://doi.org/10.1124/pr.117.014381.
-
- Berthelon, C., A. de Longcamp, A. Coquerel, and P. Denise. 2008. “Residual Effects of Zolpidem, Zopiclone and Flunitrazepam on the Processing of Visual Information in Driving Context.” European Review of Applied Psychology 58, no. 2 (June): 111–116. https://doi.org/10.1016/j.erap.2006.06.001.
-
- Billiard, M., A. Besset, C. de Lustrac, and L. Brissaud. 1987. “Dose‐Response Effects of Zopiclone on Night Sleep and on Nighttime and Daytime Functioning.” supplement, Sleep 10, no. S1 (April): 27–34. https://doi.org/10.1093/sleep/10.suppl_1.27.
-
- Bocca, M. L., S. Marie, V. Lelong‐Boulouard, et al. 2011. “Zolpidem and Zopiclone Impair Similarly Monotonous Driving Performance After a Single Nighttime Intake in Aged Subjects.” Psychopharmacology 214, no. 3: 699–706. https://doi.org/10.1007/s00213‐010‐2075‐5.
-
- Bosch, E. L., I. E. C. Sommer, and D. J. Touw. 2025. “The Influence of Female Sex and Estrogens on Drug Pharmacokinetics: What Is the Evidence?” Expert Opinion on Drug Metabolism & Toxicology 20: (March): 1–11. https://doi.org/10.1080/17425255.2025.2481891.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
